MAP2K7 and melanoma: Recently, the US Food and Drug Administration (FDA) approved the use of another PD-L1 inhibitor, atezolizumab, with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib for the treatment of patients with BRAFV600 mutation-positive advanced melanoma based on the results of the IMspire150 study (ClinicalTrials.gov identifier: NCT02908672).